October 19, 2016 11:44 AM EDT

Liver tox cases force Daiichi Sankyo to curtail recruitment for PhIII trial of a ‘breakthrough’ drug

John Carroll

Editor & Founder

Two cases of serious liver toxicity forced investigators to suspend enrollment on Daiichi Sankyo’s Phase III program for its “breakthrough” drug pexidartinib (PLX3397). But both …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Liver tox cases force Daiichi Sankyo to curtail recruitment for PhIII trial of a ‘breakthrough’ drug

John Carroll

Editor & Founder

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

New fund will pressure flailing biotechs, as investor frustration boils over

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

J&J reports durability data for bladder cancer 'pretzel' drug after FDA filing

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Liv­er tox cas­es force Dai­ichi Sankyo to cur­tail re­cruit­ment for PhI­II tri­al of a ‘break­through’ drug

Editor & Founder

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Liver tox cases force Daiichi Sankyo to curtail recruitment for PhIII trial of a ‘breakthrough’ drug